Xanthigen® Promotes Healthy Weight, Liver

MOSCOW, RussiaAccording to a recent study published in Diabetes, Obesity and Metabolism, Xanthigen® (from P.L. Thomas), a novel, patent-pending, composition of pomegranate oil standardized for punicic acid and brown seaweed extract standardized for fucoxanthin, promoted weight loss, reduced body and liver fat content, and improved liver function tests in obese non-diabetic women (2010;12:7281).

The double blind, randomized, placebo-controlled study, assessed 151 non-diabetic, obese premenopausal women with liver fat content above 11 percent (non-alcoholic fatty liver disease (NAFLD)) n=113, and below 6.5 percent (normal liver fat (NLF)) n=38. Xanthigen-600/2.4 mg (300 mg PSO + 300 mg brown seaweed extract containing 2.4 mg fucoxanthin) resulted in statistically significant reduction of body weight, waist circumference (NAFLD group only), body and liver fat content, liver enzymes (NAFLD group only), serum triglycerides and C-reactive protein. Weight loss and reduction in body and liver fat content occurred earlier in patients with NLF than in patients with NAFLD. Fucoxanthin (more than 2.4 mg) and Xanthigen-400/1.6 mg (200 mg PSO + 200 mg brown seaweed extract containing 1.6 mg fucoxanthin) significantly increased resting energy expenditure (REE) in NAFLD subjects compared to placebo.

Xanthigen offers a mechanism for unloading the triglycerides from the liver in patients with obesity and NAFLD, which improves metabolism, lowers body fat and lowers body weight, stated Vladimir Badmaev, M.D., Ph.D., director of medical & scientific affairs, P.L. Thomas.